Letter to the editor commenting on the phase 2 retatrutide obesity trial. Part of the correspondence published in NEJM following the primary trial results, raising a distinct perspective, comparison, or concern about the triple hormone receptor agonist's 24% weight loss finding or its clinical implications.
Bisson, Arnaud; Fauchier, Grégoire; Fauchier, Laurent